Insmed (INSM) Current Assets (2010 - 2026)
Insmed (INSM) posted Current Assets of $1.6 billion for Q2 2026, up 1.29% on a QoQ basis from $1.6 billion in Q1 2026, and down 21.51% year-over-year from $2.1 billion in Q2 2025.
Analysis
Insmed (INSM) Current Assets (2010 - 2026) Analysis & Trends
Insmed has reported Current Assets for 17 years, with the latest figure at $1.6 billion in Q2 2026.
- On a quarterly basis, Current Assets fell 21.51% year-over-year to $1.6 billion in Q2 2026; TTM through Jun 2026 was $1.6 billion, a 21.51% decrease from a year earlier, with the FY2025 full-year figure at $1.8 billion, up 10.64% from the prior year.
- Current Assets was $1.6 billion for Q2 2026 at Insmed, up from $1.6 billion in the prior quarter.
- The five-year high for Current Assets was $2.1 billion in Q2 2025, with the low at $632.2 million in Q3 2022.
- Average Current Assets over 5 years is $1.3 billion, with a median of $1.3 billion recorded in 2022.
- The sharpest annual moves came in 2022 and 2025: Current Assets sank 35.01% in 2022, then soared 84.88% in 2025.
- Over 5 years, Current Assets stood at $1.3 billion in 2022, then declined by 27.04% to $929.1 million in 2023, then surged by 74.55% to $1.6 billion in 2024, then grew by 10.64% to $1.8 billion in 2025, then retreated by 8.93% to $1.6 billion in 2026.
- The last three Current Assets figures came in at $1.6 billion (Q2 2026), $1.6 billion (Q1 2026), and $1.8 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 34.96 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 13.95 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 12.54 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 18.45 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 8.07 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 5.82 Bn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 4.62 Bn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 7.31 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 1.63 Bn |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | 17.78 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.63 Bn |
| Mar 31, 2026 | 1.61 Bn |
| Dec 31, 2025 | 1.79 Bn |
| Sep 30, 2025 | 1.93 Bn |
| Jun 30, 2025 | 2.08 Bn |
| Mar 31, 2025 | 1.40 Bn |
| Dec 31, 2024 | 1.62 Bn |
| Sep 30, 2024 | 1.65 Bn |
| Jun 30, 2024 | 1.42 Bn |
| Mar 31, 2024 | 758.72 Mn |
| Dec 31, 2023 | 929.06 Mn |
| Sep 30, 2023 | 926.58 Mn |
| Jun 30, 2023 | 1.05 Bn |
| Mar 31, 2023 | 1.13 Bn |
| Dec 31, 2022 | 1.27 Bn |
| Sep 30, 2022 | 632.17 Mn |
| Jun 30, 2022 | 674.73 Mn |
| Mar 31, 2022 | 756.14 Mn |
| Dec 31, 2021 | 837.04 Mn |
| Sep 30, 2021 | 958.98 Mn |